KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $17.6 million.

  • Emergent BioSolutions' Change in Inventory fell 222.22% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.5 million, marking a year-over-year increase of 23838.38%. This contributed to the annual value of $24.5 million for FY2024, which is 418333.33% up from last year.
  • Emergent BioSolutions' Change in Inventory amounted to $17.6 million in Q3 2025, which was down 222.22% from $24.7 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Change in Inventory peaked at $99.9 million during Q1 2021, and registered a low of -$45.7 million during Q4 2022.
  • Its 5-year average for Change in Inventory is $10.1 million, with a median of $8.6 million in 2021.
  • Its Change in Inventory has fluctuated over the past 5 years, first crashed by 63139.53% in 2022, then surged by 1790000.0% in 2024.
  • Emergent BioSolutions' Change in Inventory (Quarter) stood at $8.6 million in 2021, then crashed by 631.4% to -$45.7 million in 2022, then soared by 43.98% to -$25.6 million in 2023, then soared by 57.03% to -$11.0 million in 2024, then soared by 260.0% to $17.6 million in 2025.
  • Its Change in Inventory was $17.6 million in Q3 2025, compared to $24.7 million in Q2 2025 and $2.2 million in Q1 2025.